Medpace Holdings Inc vs First Trust Cloud Computing ETF — how do they compare? Medpace Holdings Inc trades at $530 (market cap $15.08B), while First Trust Cloud Computing ETF trades at $135.77. Which is the better fit depends on your goals.
| MEDP | SKYY | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | — |
52-Week High | $620.59 | $155.17 |
52-Week Low | $308.88 | $104.16 |
Enterprise Value | $14.55B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
SKYY trades at $136.02, down 0.06% on the day, with a bullish technical signal driven by moving averages. The ETF offers diversified exposure to the cloud computing sector, though key valuation and profitability metrics are not disclosed in the provided data. Recent news highlights ongoing investor interest in technology ETFs and the growth potential of AI-driven cloud platforms.
The outlook for SKYY is supported by strong inflows into technology ETFs and enterprise AI spending, but risks include sector volatility and competitive pressures. Analyst coverage remains positive on cloud computing's long-term growth, though specific price targets and institutional holdings data are needed for a fuller assessment.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →